- Home
- ECO vs PHVS Comparison
ECO vs PHVS Comparison
Compare ECO & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECO | PHVS |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Greece | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ECO | PHVS |
|---|---|---|
| Price | $35.60 | $23.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $37.00 | ★ $39.44 |
| AVG Volume (30 Days) | 344.2K | ★ 563.8K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | ★ 5.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $349,886,578.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.29 | N/A |
| P/E Ratio | $15.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.91 | $11.51 |
| 52 Week High | $39.77 | $29.80 |
Technical Indicators
Market Signals| Indicator | ECO | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 46.50 |
| Support Level | $35.39 | $23.15 |
| Resistance Level | $36.32 | $24.63 |
| Average True Range (ATR) | 0.88 | 2.04 |
| MACD | -0.33 | -0.39 |
| Stochastic Oscillator | 26.41 | 10.08 |
Price Performance
Historical ComparisonAbout ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.